Amylyx Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Feb 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 22, 2024

AMLX$30.21+2.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AMYLYX PHARMACEUTICALS, INC.
Date: February 22, 2024	By:	/s/ Joshua B. Cohen
		Joshua B. Cohen
		Co-Chief Executive Officer
Date: February 22, 2024	By:	/s/ Justin B. Klee
		Justin B. Klee
		Co-Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Joshua B. Cohen
Name	Title	Date
/s/ Joshua B. Cohen	Co-Chief Executive Officer and Director (Principal Executive Officer)	February 22, 2024
/s/ Justin B. Klee	Co-Chief Executive Officer and Director (Principal Executive Officer)	February 22, 2024
Justin B. Klee
/s/ James M. Frates	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	February 22, 2024
James M. Frates
/s/ George Mclean Milne Jr.	Director	February 22, 2024
George Mclean Milne Jr. Ph.D.
/s/ Paul Fonteyne	Director	February 22, 2024
Paul Fonteyne, M.S., M.B.A.
/s/ Daphne Quimi	Director	February 22, 2024
Daphne Quimi
/s/ Karen Firestone	Director	February 22, 2024
Karen Firestone

Amylyx Pharmaceuticals, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.